Zimmer Biomet Recasts 2025 Segment Reporting in 8-K

What Happened

• Zimmer Biomet Holdings, Inc. filed a Current Report on Form 8‑K on August 5, 2026 to recast certain financial information and related disclosures in its Annual Report on Form 10‑K for the year ended December 31, 2025 (original 10‑K filed Feb 20, 2026).
• The recast follows changes, effective in the quarter ended March 31, 2026, in which responsibilities of senior leaders reporting to the company’s chief operating decision maker (CODM) and the operating profit information they provide were reorganized. As a result, certain businesses and product-category expenses were reallocated among operating segments.
• Zimmer Biomet filed Exhibit 99.1 containing the recast sections; the filing specifically recasts Part II, Item 7 (Management’s Discussion and Analysis) and Part II, Item 8 (Financial Statements and Supplementary Data) of the 2025 Form 10‑K.

Key Details

• Effective quarter: changes took effect in the quarter ended March 31, 2026.
• Primary reclassifications: Foot & Ankle business results in Europe, Middle East & Africa (EMEA) and Asia Pacific (APAC) are now included in the Americas operating segment.
• Expense reallocations: certain centralized product-category expenses (e.g., centralized R&D and global marketing) are now included in the Americas operating segment results.
• Scope of recast: Exhibit 99.1 only recasts the specified 10‑K sections for segment composition; it is not an amendment or restatement of the 2025 Form 10‑K and does not otherwise update the MD&A except as needed for the segment changes.

Why It Matters

• For investors, this changes how revenue and operating profit are presented by operating segment, which affects comparability of prior-period segment results and any analysis based on segment performance.
• The company advises readers to review Exhibit 99.1 alongside the 2025 Form 10‑K and subsequent filings (10‑Q and 8‑K) for full context; the recast clarifies segment reporting but does not alter the underlying annual filing beyond those adjusted disclosures.